Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Stopped early · Phase 1

Conditions studied: Solid Malignancies

In brief

This study is being conducted to assess the safety, tolerability and PK of AZD1480 in patients with advanced solid malignancies.

Key facts

Study ID

NCT01112397

Run by

AstraZeneca

People needed

72

Starts

2010-04-01

Expected to finish

2012-09-01

Last updated by the study team

2013-07-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with advanced solid cancer without available therapy in the escalation phase and mutation positive NSCLC or non-smokers with other primary tumors lung metastasis in the expansion phase
• ECOG Performance Status 0-1
• Evidence of post-menopausal status in females or males willing to use barrier contraception

You may not qualify if…

• Prior therapy with any JAK2 medications
• Significant lung disorder or lung disease. Previous radiation therapy to chest wall or chest infection requiring antibiotic treatment within 21 days before study screening. Evidence of significant pulmonary hypertension or COPD
• Eye disease of the cornea

Where it is running

• Research Site — Aurora, Colorado, United States
• Research Site — Detroit, Michigan, United States
• Research Site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.